Cite
HARVARD Citation
Wongchenko, M. et al. (2018). Association of programmed death ligand‐1 (PD‐L1) expression with treatment outcomes in patients with BRAF mutation‐positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib. Pigment cell & melanoma research. pp. 516-522. [Online].